10.08.2013 Views

Report in English with a Dutch summary (KCE reports 45A)

Report in English with a Dutch summary (KCE reports 45A)

Report in English with a Dutch summary (KCE reports 45A)

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

<strong>KCE</strong> <strong>reports</strong> vol.45 Screen<strong>in</strong>g for Colorectal Cancer: Appendices 165<br />

Nr Title Issued by Type<br />

4 Screen<strong>in</strong>g for colorectal<br />

cancer: recommendations<br />

and rationale 182.<br />

5 Recommendations on cancer<br />

screen<strong>in</strong>g <strong>in</strong> the European<br />

Union 179.<br />

U.S. Preventive<br />

Services Task Force<br />

(USPSTF)<br />

EU Advisory<br />

Committee on<br />

Cancer Prevention<br />

(ACPG)<br />

Target<br />

population<br />

CPG Men and women <br />

50 y. old<br />

HC/PR Men and women<br />

aged 50 to<br />

approximately 74 y.<br />

Screen<strong>in</strong>g<br />

methods /<br />

options<br />

considered<br />

1. home FOBT<br />

2. FS<br />

3. home FOBT +<br />

FS<br />

4. Colonoscopy<br />

FOBT screen<strong>in</strong>g<br />

test +<br />

colonoscopy for<br />

the follow-up of<br />

test positive cases<br />

Interval<br />

1. FOBT yearly<br />

2. FS every 5 y.<br />

3. home FOBT +<br />

FS<br />

4. Colonoscopy<br />

every 10 y.<br />

annually or<br />

biennially<br />

Support<strong>in</strong>g<br />

evidence classes<br />

& quality rat<strong>in</strong>g<br />

1. FOBT: Direct<br />

evidence, Level I,<br />

<strong>in</strong>ternal validity<br />

good, external<br />

validity good<br />

2. FS: Direct<br />

evidence, Level II,<br />

<strong>in</strong>ternal validity<br />

good, external<br />

validity fair<br />

3. FOBT and FS:<br />

Direct evidence<br />

not sure, Level II,<br />

<strong>in</strong>ternal validity<br />

fair, external<br />

validity fair<br />

4. BCBE: No<br />

direct evidence,<br />

Level III, <strong>in</strong>ternal<br />

validity fair,<br />

external validity<br />

fair<br />

5. Colonoscopy:<br />

Direct evidence<br />

not sure, Level II,<br />

<strong>in</strong>ternal validity<br />

fair, external<br />

validity fair<br />

Evidence<br />

discussed but not<br />

rated<br />

Rat<strong>in</strong>g<br />

system<br />

See<br />

Appendix 2<br />

(UPSTF)<br />

Conclusions<br />

The USPSTF strongly recommends that cl<strong>in</strong>icians<br />

screen men and women aged 50 and older who<br />

are at average risk for colorectal cancer. For<br />

those at higher risk, such as those <strong>with</strong> a firstdegree<br />

relative diagnosed <strong>with</strong> colorectal cancer<br />

before age 60, it is reasonable to beg<strong>in</strong> screen<strong>in</strong>g<br />

at a younger age. Screen<strong>in</strong>g options for colorectal<br />

cancer <strong>in</strong>clude home fecal occult blood test<br />

(FOBT), FS, the comb<strong>in</strong>ation of home FOBT and<br />

FS, colonoscopy, and double-contrast barium<br />

enema. The choice of screen<strong>in</strong>g strategy should<br />

be based on patient preferences, medical<br />

contra<strong>in</strong>dications, patient adherence, and<br />

resources for test<strong>in</strong>g and follow-up<br />

There are <strong>in</strong>sufficient data to determ<strong>in</strong>e which<br />

particular screen<strong>in</strong>g strategy is best <strong>in</strong> terms of<br />

the balance of benefits and harms or costeffectiveness.<br />

Studies reviewed by the USPSTF<br />

<strong>in</strong>dicate that colorectal cancer screen<strong>in</strong>g is likely<br />

to be cost effective (cost<strong>in</strong>g less than $30,000 per<br />

additional year of life ga<strong>in</strong>ed) regardless of which<br />

screen<strong>in</strong>g method is used.<br />

None As colorectal cancer is a major health problem <strong>in</strong><br />

many European countries fecal occult blood<br />

screen<strong>in</strong>g should be seriously considered as a<br />

preventive measure. The decision on whether or<br />

not to embark on these screen<strong>in</strong>g programs must<br />

depend on the availability of the professional<br />

expertise and the priority sett<strong>in</strong>g for healthcare<br />

resources. If screen<strong>in</strong>g programs are<br />

implemented they should use the fecal occult<br />

blood screen<strong>in</strong>g test and colonoscopy should be<br />

used for the follow-up of test positive cases.<br />

Screen<strong>in</strong>g should be offered to men and women<br />

aged 50 years to approximately 74 years. The<br />

screen<strong>in</strong>g <strong>in</strong>terval should be 1 or 2 years. Other<br />

screen<strong>in</strong>g methods such as immunological tests,<br />

FS and colonoscopy can at present not be<br />

recommended for population screen<strong>in</strong>g.<br />

Grades of<br />

recommendati<br />

on<br />

Grade A<br />

No grad<strong>in</strong>g<br />

(HC/PR)

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!